Company Operations by Product, Customer and Geographic Area

12 Months Ended

Dec. 31, 2016

Segment Reporting [Abstract]

Company Operations by Product, Customer and Geographic Area

Company Operations by Product, Customer and Geographic Area

The Company has determined that it operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary drug delivery technologies. The Company's Chief Operating Decision Maker is the CEO. The CEO and the Company's Board of Directors review profit and loss information on a consolidated basis to assess performance and make overall operating decisions as well as resource allocations.

The following table presents a summary of total revenues by these products for the twelve months ended December 31, 2016, 2015, and 2014: 

Revenue by Product:	2016		2015		2014
Bloxiverz	$	82,896	$	150,083	$	10,411
Vazculep	39,796		20,151		—
Akovaz	16,831		—		—
Other	7,699		2,054		1,782
Total product sales and services	147,222		172,288		12,193
License and research revenue	3,024		721		2,782
Total revenues	$	150,246	$	173,009	$	14,975

Concentration of credit risk with respect to accounts receivable is limited due to the high credit quality comprising the payer base. Management periodically monitors the creditworthiness of its customers and believes that it has adequately provided for any exposure to potential credit loss.

The following table presents a summary of total revenues by significant customer for the twelve months ended December 31, 2016, 2015, and 2014: 

Revenue by Significant Customer:	2016		2015		2014
Customer A	$	51,648	$	53,988	$	3,937
Customer B	39,359		60,420		3,859
Customer C	30,916		43,434		3,563
Customer D	17,728		—		—
Other	7,571		14,446		834
Total product sales and services	147,222		172,288		12,193
License and research revenue	3,024		721		2,782
Total revenues	$	150,246	$	173,009	$	14,975

As of December 31, 2016, the Company had three customers each of which accounted for 10% or more of the accounts receivable balance. One customer accounted for 42%, or $7,472, a second customer accounted for 24% or $4,307, and a third customer accounted for 24% or $4,291. As of December 31, 2016, the Company had no significant past due account receivable balances.

The following table summarizes revenues by geographic region for the twelve months ended December 31, 2016, 2015, and 2014:

Revenue by Geographic Region:	2016		2015		2014
United States	$	147,283	$	172,179	$	14,502
France	—		89		473
Ireland	2,963		741		—
Total	$	150,246	$	173,009	$	14,975

Currently we depend on a single contract manufacturing organization for the manufacture of Bloxiverz, Vazculep and Akovaz, and to deliver certain raw materials used in their production, from which we derive a majority of our revenues. Additionally, we purchase certain raw materials used in our products from a limited number of suppliers, including a single supplier for certain key ingredients.

Non-monetary long-lived assets primarily consist of property and equipment, goodwill and intangible assets. The following table summarizes non-monetary long-lived assets by geographic region as of December 31, 2016, 2015, and 2014:

Long-lived Assets by Geographic Region:	2016		2015		2014
United States	$	42,021	$	34,515	$	47,077
France	2,524		2,317		1,704
Ireland	202		258		—
Total	$	44,747	$	37,090	$	48,781